The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at ...

(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well ...

The start of a traditionally solid month on Wall Street saw stocks rising as Amazon.com Inc.’s $38 billion deal with OpenAI ...

The US pharma giant wants a court to stop biotech Metsera from ditching its deal for an $8.5 bln rival bid from Novo Nordisk. The Danish giant's cash comes with few strings, making the legal approach ...

George Tidmarsh denied wrongdoing at the FDA and accused senior FDA officials — including CBER chief Vinay Prasad — of wrongdoing ...

There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a ...

The FDA's top regulator of medicines has resigned after being accused of using his regulatory authority to harm a former ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...

Pfizer filed its second lawsuit against Metsera and Novo Nordisk, alleging Novo Nordisk's attempt to outbid Pfizer to acquire Metsera violates antitrust laws.